Angiopoietin-like 4 (ANGPTL4) is a glycosylated and secreted protein that functions as a regulator of cell metabolism and angiogenesis, and which has been shown to play a critical role in tumorigenesis.
CSPC Pharmaceutical Group Ltd. has announced FDA approval of an IND application for JMT-106, a bispecific fusion protein drug, for glypican-3 (GPC3)-positive solid tumors.
Hemispherian AS has been granted NOK16 million (US$1.54 million) by the Research Council of Norway, which the company intends to use to support development of its drug candidates aimed at treating platinum-resistant ovarian cancers.
Repare Therapeutics Inc. has identified membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Simcere Zaiming Pharmaceutical Co. Ltd. has synthesized antibody-drug conjugates (ADC) comprising humanized monoclonal antibodies targeting CDH6 covalently linked to a camptothecin analogue through a linker.
Buying out Immunogen Inc. in a whopper cash deal valued at about $10.1 billion, Abbvie Inc. has major plans for an expanded label on the antibody-drug conjugate Elahere (mirvetuximab soravtansine-gynx), already approved for treating platinum-resistant ovarian cancer.
Medicovestor Inc. has successfully completed an oversubscribed seed financing round with the aim of advancing its antibody-drug conjugate (ADC) platforms and drug candidates.
Researchers from Nkgen Biotech Inc. have developed an anti-HER2 CAR NK cell therapy, named SNK-02, as a potential immunotherapeutic for HER2-overexpressing tumors. SNK-02 was tested in a xenografted murine model of cancer.
